Optimization of the magnetic labeling of human neural stem cells and MRI visualization in the hemiparkinsonian rat brain by Ramos-Gómez, M. et al.
Ramos-Gómez et al. Journal of Nanobiotechnology  (2015) 13:20 
DOI 10.1186/s12951-015-0078-4RESEARCH Open AccessOptimization of the magnetic labeling of human
neural stem cells and MRI visualization in the
hemiparkinsonian rat brain
Milagros Ramos-Gómez1,2*, Emma G Seiz3 and Alberto Martínez-Serrano3*Abstract
Background: Magnetic resonance imaging is the ideal modality for non-invasive in vivo cell tracking allowing for
longitudinal studies over time. Cells labeled with superparamagnetic iron oxide nanoparticles have been shown to
induce sufficient contrast for in vivo magnetic resonance imaging enabling the in vivo analysis of the final location
of the transplanted cells. For magnetic nanoparticles to be useful, a high internalization efficiency of the particles is
required without compromising cell function, as well as validation of the magnetic nanoparticles behaviour inside
the cells.
Results: In this work, we report the development, optimization and validation of an efficient procedure to label
human neural stem cells with commercial nanoparticles in the absence of transfection agents. Magnetic
nanoparticles used here do not affect cell viability, cell morphology, cell differentiation or cell cycle dynamics.
Moreover, human neural stem cells progeny labeled with magnetic nanoparticles are easily and non-invasively detected
long time after transplantation in a rat model of Parkinson’s disease (up to 5 months post-grafting) by magnetic resonance
imaging.
Conclusions: These findings support the use of commercial MNPs to track cells for short- and mid-term periods after
transplantation for studies of brain cell replacement therapy. Nevertheless, long-term MR images should be interpreted
with caution due to the possibility that some MNPs may be expelled from the transplanted cells and internalized by host
microglial cells.
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Neural stem cells (NSCs) represent a source of cells for
regenerative medicine, in particular for cell replacement
therapies both in the clinical and pre-clinical experimen-
tal settings. One of the goals of stem cell research is the
in vitro and in vivo generation of neurons which could
turn to be optimal candidates to replace specific lost
neurons, for instance in Parkinson’s disease (PD), in
which the A9 subtype of dopaminergic neurons (DAn)
in the Substantia nigra (SN) are lost [1]. Previous clinical
studies of cell replacement in PD were based on the* Correspondence: milagros.ramos@ctb.upm.es; amserrano@cbm.csic.es
1Centre for Biomedical Technology, Polytechnic University of Madrid, 28223
Madrid, Spain
3Department of Molecular Biology and Center of Molecular Biology “Severo
Ochoa”, Autonomous University of Madrid-C.S.I.C, 28049 Madrid, Spain
Full list of author information is available at the end of the article
© 2015 Ramos-Gómez et al.; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.transplantation of fresh human fetal ventral mesenceph-
alic (VM) tissue into the caudate and putamen of PD
patients [1,2]. These initial experiments showed practical
and ethical issues such as the need to obtain tissue from
six to seven human fetuses to provide enough cells for
one patient’s transplantation, the lack of reproducibility
between centers, poor survival in some cases, and the
appearance of serious adverse side-effects in some
patients. Recent work has thus aimed to obtain suitable
sources of human NSCs (hNSCs) with the capacity to
differentiate into DAn endowed with the required,
genuine properties of Substantia Nigra pars compacta
neurons (SNpc) lost in PD [3,4].
Recent pre-clinical research has demonstrated that
immortalized human NSCs, derived from VM (hVM1 cell
line) and modified for the elevated expression of Bcl-XL
(hVM1-highBcl-XL cells), have the potential to differentiateCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in hemiparkinsonian rats, these hVM cells survive, inte-
grate, and differentiate into DAn, alleviating behavioral
motor asymmetry and skilled paw use [5,9,10]. Thus, hVM1
cells and their derivatives represent a helpful tool for the
development of cell therapies for neurodegenerative dis-
eases, Parkinson disease in particular.
Tracking noninvasively the long-term spatial destin-
ation and final residence of transplanted cells in vivo, to
monitor their survival, migration, differentiation and re-
generative impact, has become a critical methodology in
evaluating the efficacy of stem cell therapy procedures.
Until now, it was only the behavioral testing or the DA
determination by in vivo HPLC and the subsequent
histological analysis the available methods used to evalu-
ate grafting outcome, viability and differentiation of
transplanted cells in hemiparkinsonian animal models.
But, optimally, research in cell replacement therapy re-
quires of non-invasive and sensitive imaging techniques
to track the fate of transplanted cells; these techniques
would increase reliability and reduce the total number of
animals used in these experiments.
Labeling cells with magnetic nanoparticles (MNPs) has
been shown to induce sufficient contrast for magnetic
resonance imaging (MRI) of cells in the brain [11-15].
Therefore, MRI, in combination with other in vivo mo-
lecular imaging techniques, like PET, can provide insights
into different cellular processes, including localization and
migration of the cells, cell survival and proliferation kinet-
ics, and cell differentiation patterns, which can aid clinical
implementation of cell therapy [16].
Most labeling techniques currently take advantage of
either the attachment of MNPs to the stem cell surface
or the internalization of MNPs by endocytosis. Surface
labeling normally results in lower iron content per cell
and promotes a rapid reticulo-endothelial recognition
and clearance of labeled cells [17,18]. Therefore, endo-
cytosis of MNPs during in vitro cell cultivation stands as
the preferred labeling method.
The most commonly used MNPs to label cells, dextran
coated superparamagnetic iron oxide (SPIO) nanoparti-
cles, as the ones used in the present study, do not effi-
ciently label either nonphagocytic or non–rapidly dividing
mammalian cells in vitro [19]. Consequently, these con-
trast agents are not used as isolated reagents to label
hNSCs or other mammalian cells [20-22]. In most cases,
internalization of nanoparticles by hNSCs requires the use
of transfection agents (TAs), like protamine sulfate (PS) or
poly-L-lysine (PL) to achieve an efficient labeling of the
stem cells. TAs coat MNPs by means of electrostatic inter-
action with dextran-coated nanoparticles and help intern-
alizing them into cells. PS, conventionally used to reverse
heparin anticoagulation, has been used as a cationic TA to
label human mesenchymal stem cells and hematopoieticstem cells with SPIO nanoparticles [19]. The use of PL
complexed with MNPs also reported a high labeling effi-
ciency of NSCs, 80% [23]. However, the use of TAs to label
cells might have a harmful side effect decreasing cell via-
bility, since most TAs are toxic to cells when used alone
and not complexed to DNA [19]. In addition, the use of
relative high concentrations of magnetic nanoparticles to
label hNSCs might be toxic or affect some of their func-
tional properties, causing alterations in their differenti-
ation processes. Thus, an extensive study of the properties
of NSCs labeled with MNPs must be carried out to iden-
tify the effects of MNPs on hNSCs biology.
The aim of the present study was to efficiently label
cells using magnetic nanoparticles detectable by MRI
and to determine the effects of such particles on morph-
ology, cell cycle and differentiation capacity of hVM
cells. Here we report the development and validation of
an efficient protocol to label hNSCs using several com-
mercial magnetic nanoparticles as contrast agents for
MRI. We optimized the incubation times and the con-
centration of MNPs to label hNSCs in the absence of
any transfection agents that could damage the cellular
integrity, in order to prevent impairment of the cells’
functional properties.
Our results demonstrate that the use of MNPs to label
hNSCs is feasible, efficient and safe for MRI tracking fol-
lowing grafting of hNSCs into hemiparkinsonian rat
brain. The fate of MNPs-labeled hNSCs grafted into
hemiparkinsonian rats can be successfully visualized
using MRI at different time points, up to 5 months after
transplantation.
Materials and methods
Cell cultures
Cell isolation and immortalization were described previ-
ously by Villa [8] and Courtois [9]. Briefly, human ventral
mesencephalic cells were isolated from a 10-week-old
aborted fetus (Lund University Hospital). Tissue procure-
ment was in accordance with the Declaration of Helsinki
and in agreement with the ethical guidelines of the
European Network of Transplantation. Immortalization was
carried out by infection with a retroviral vector coding for
v-myc (LTR-vmyc-SV40p-Neo-LTR) generating the hVM1
cell line. The hVM1 polyclonal cell line was infected at
passage 6 with a Bcl-XL coding (LTR-Bcl-XL-IRES-rhGFP-
LTR) retroviral vector, to enhance their neurogenic capacity
[24]. After infection, the cells were selected by fluorescence-
activated cell sorting (FACS) generating the hVM1 Bcl-XL
cell line (referred here as hVM to abbreviate). Both cell lines
were routinely cultured under standard conditions as de-
scribed before [8,9]. Briefly, cells were cultured on 10 μg/ml
polylysine-pretreated plasticware in epidermalgrowth factor
(EGF) and basic fibroblast growth factor (FGF) (20 ng/ml
each; R&D Systems) supplemented chemically defined
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max (Invitrogen), 1% Albumax (Invitrogen), 50 mM Hepes
(Invitrogen), 0.6% glucose, N2 supplement (Invitrogen), 1x
nonessential amino acids and penicillin/streptomycin,), re-
ferred to hereafter as “proliferation medium”. To induce cell
differentiation, cells were seeded at 105cells/cm2 in prolifera-
tion medium on poly-L-lysine-treated glass coverslips. After
24 h, proliferation medium was replaced by differentiation
medium without EGF or FGF, and containing 1 mM
dibutyryl-cAMP (Sigma) and 2 ng/ml human recombinant
glial cell-derived neurotrophic factor (GDNF) (Prepro-
tech)). Differentiation medium was changed every second
day until the end of the experiment. Cells were prolifer-
ated and differentiated at 37°C and 95% humidity in a low
oxygen atmosphere (5% O2, 5% CO2, in a dual CO2/O2 in-
cubator (Forma)).
Uptake of MNPs by hVM cells
Cell labeling with MNPs
hVM cells were seeded on glass coverslips at a density of
50,000 cells/cm2. After 24 h with proliferation medium,
different types of SPIO nanoparticles were added while
varying several parameters such as concentration, pre-
coating with transfection agents and the time of incuba-
tion. For these studies the following conditions were
used: i) different core diameter types (all dextran
coated): 250 nm (G.Kisker), 50 nm (G.Kisker), 100 nm
(Endorem) and 100 nm-Cy3conjugated (Chemicell); ii)
concentration: 50, 100 or 300 μgFe/ml of culture
medium; iii) incubation time: 3, 6, 12, 24 or 72 h; iv)
pre-treatment of MNPs with transfection agents: un-
treated (control) and treated with poly-lysine (0.03
μgPL/μgFe,Sigma) or protamine sulfate (0.5 μgPS/g Fe,
Sigma). For pre-treatment MNPs were maintained in
proliferation medium with constant stirring for 24 h at
room temperature before being added to cell cultures.
Following the desired incubation time, cells were
rinsed with culture medium and PBS to remove unincor-
porated MNPs. Subsequently, the cells were differenti-
ated and fixed with 4% of paraformaldehyde (Merck) in
0.1 M phosphate buffer at pH 7.4 for 15 minutes at
room temperature. Fixed cells were blocked for 1 h in
PBS containing 10% normal horse serum, 0.25% Triton
X-100 and incubated overnight at 4°C with a monoclonal
antibody to mark the dextran coating of the MNPs
(except in the case of 100 nm-Cy3) using an antibody
anti-dextran (1:500, Stem Cell Technologies). After-
wards, cells were rinsed and incubated with an anti-
mouse Cy3-conjugated secondary antibody (1:500,
Jackson Immunoresearch). Last, the cells were incu-
bated with ToPro-3 (1:750, Invitrogen) for nucleic acid
staining and phalloidin A488 to mark F-actin fila-
ments and define cell shape. The magnitude of MNPs
uptake was determined as the proportion of cells withgreen fluorescent cytosolic dots corresponding to
MNPs compared to the total number of cells identified
by the nuclear counterstaining with ToPro-3 using a
confocal microscope coupled to a LSM510 Axio-
vert200 inverted microscope (Zeiss) .
Cell viability assays
Cell viability in unlabeled (control) cultures and in those
labeled with MNPs was evaluated by the MTT assay at
day 0 and 7 of differentiation. Cells were seeded at a
density of 50,000 cells/cm2 in 0.5 ml culture medium.
After labeling cells with MNPs for 72 h, 125 μl of 5 mg/
ml MTT (Sigma M-2128) were added and the incuba-
tion was left to proceed for 60 min at 37°C. Then 1 ml
of DMSO was added per well to extract the formazan
and absorbance at 570 nm was determined.
Cell cycle analysis
To analyze the effect of MNPs on cell cycle, we per-
formed a cell cycle analysis in unlabeled and MNP-
labeled cells (100 nm, 50μgFe/ml) by propidium iodide
staining and flow cytometry using the technique of
Nicoletti [25]. The cells were seeded at a density of
30,000 cells/ cm2. After 24 and 48 h of incubation with
the MNPs, the cells were trypsinized and washed in PBS
(without Ca/Mg2+). Cells were centrifuged 10 min at
1000 rpm at 4°C and the cell pellets were mixed with
1 ml of cold 70% ethanol using the vortex. After18h fix-
ation in ethanol at -20°C the samples were resuspended
carefully and centrifuged 5 min at 1500 rpm. The super-
natant was discarded and the pellet was resuspended in
0.5 ml of buffer cycle (50 μg/ml propidium iodide, 0.1%
sodium citrate, 50 μg/ml ribonuclease A in PBS without
Ca2+ or Mg2+), and incubated 30 min at room temperature
for staining. The cells were then analyzed by flow cytome-
try (flow cytometer FACSCalibur, Becton Dickinson) using
the 488 nm argon laser for excitation and filter 585/42 nm
for the collection of emission (channel FL-2). The intensity
of fluorescence represented in linear scale (cell cycle distri-
bution) and data were analyzed for quantification of the
regions sub-G0-G1 (less than 2n of DNA and fragmented
DNA), G0-G1 (2n DNA) and S-G2-M (mitotic phase ac-
tive, i.e. an amount of DNA between 2n and 4n). A total
of 10.000 events were acquired and analyzed using FloJo7
software. Samples were run in biological triplicates.
Immunocytochemistry
Unlabeled cells and cells labeled with MNPs (50 and
100 nm size; 50μgFe/ml) for 72 h, were grown on glass
coverslips in differentiation medium for the specified
time (4 and 7 days) and fixed with paraformaldehyde
(PFA, Merck) at 4% in 0.1 M phosphate buffer at pH 7.4,
for 15 minutes at room temperature. After 3 washes in
PBS, samples were blocked for 1 h with a solution of
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Tecnhologies) or goat serum (Gibco/Life Technologies)
and 0.25% nonionic detergent Triton X-100 (Merck).
Subsequently, cells were incubated overnight at 4°C with
primary antibodies dissolved in a PBS solution with
0.25% triton and 1% horse-goat serum. To evaluate the
possible effect of the MNPs in cell differentiation the fol-
lowing antibodies were used: nestin (day 0, 1:1000,
Abcam; 1:500 BD Bioscience) and β-III-tubulin (day 7,
1:1000, Sigma), TH (day 7, 1:1000sigma) and GFAP (day
7, 1:1000 Sigma). To study the intracellular localization
of MNPs the following antibodies were used: anti-
manosidase II (day 7, 1:100, Millipore), anti-EEA1 (day
7, 1:200, BD Transduction) and anti-CD63 (day 7, 1:100,
DSHB). After removing the solution with primary anti-
body and rinsing, the samples were incubated with sec-
ondary antibody conjugated with different fluorophores
in PBS for 30 min at room temperature (1:500, Cy3, Cy5
or Alexa488, Jackson Inmunoresearch). Finally, nuclei
were counterstained with Hoechst 33258 (0.2 μg/ml in
PBS, Molecular Probes) or To-Pro-3 (1:500, Invitrogen).
After the labeling, the coverslips were washed in PBS
and distilled H2O, allowed to dry and mounted with
Mowiol (Calbiochem).
MNP labeling decay with passages in culture
Cells were labeled with MNPs (50 and 100 nm-Cy3
50μgFe/ml) for 72 hours in p60 plates (3x104 cells/cm2).
Subsequently, the cultures were trypsinized and seeded
on glass coverslips (passage 0) and split to new p60
plates. After two days, cells of these plates were trypsinized
and seeded on glass coverslips (passage 1), remaining cells
were split to new p60 plates after 48 h in culture and seeded
at the same initial density (3x104 cells/cm2). We proceeded
up to the passage 4. Cells were fixed and immuno-stained
to detect dextran, Phalloidin A488 and To-Pro-3. Then, the
percentage of cells containing MNPs at each passage was
determined using a LSM510 laser confocal Microscope
coupled to an Axiovert200 (Zeiss) inverted microscope.
Animal Experimentation
Lesion and Transplantation Procedures
Experiments were carried out according to the guide-
lines of the European Community (Directive 86/609/
ECC, Directive 2010/63/EU) observing the 3Rs princi-
ples, and in accordance with the Society for Neurosci-
ence recommendations. Animals used in this study were
3-month-old female Sprague-Dawley rats (Harlan),
weighing 200–250 g at the beginning of the experi-
ment, housed in a temperature- and humidity-
controlled room, under 12-h light/dark cycles, with
ad libitum access to food and water. Cells (in prolifera-
tive state) for transplantation in intact brains were dis-
persed and resuspended in Hanks’ balanced salt solution(Invitrogen) at a density of 105 cells/μl. Cell suspensions
(3x105 cells in 3 μl) were injected into the left striatum
(control unlabeled cells) and in the right striatum (cells la-
beled with 100 nm MNPs-Cy3 at 50 μg/ml for 72 h) at the
following coordinates (in mm): anteroposterior -1; medio-
lateral +/-3; dorsoventral-4.5 (from dura), with the tooth
bar set at -2.3. Hemiparkinsonian rats received a 6-
hydroxydopamine (6-OH-DA) injection (9 μg/3 μl dis-
solved in 0.9% saline containing 0.2 mg/ml ascorbic acid;
Sigma) in the right median forebrain bundle at the follow-
ing stereotaxic coordinates (tooth bar set at -3.3 mm): an-
teroposterior -3.7 mm; mediolateral -1.6 mm (both from
bregma); dorsoventral -8.8 mm from dura. The injection
rate was 1 μl/min, and the syringe was kept in place for an
additional 5 min before being slowly retracted. Four weeks
after the lesion, the rats were tested for rotational behavior
in automated rotometer bowls (Panlab) following an injec-
tion of apomorphine (0.2 mg/ml; Sigma) and 1 week later
with D-amphetamine sulfate (5 mg/kg, intraperitoneally
(Sigma); Rotational scores were collected every 2 min for
60 min for D-amphetamine test and 40 min for apo-
morphine test in a computer-assisted rotometer system
(Panlab). Only rats exhibiting 5 or more ipsilateral rota-
tions/min after D-amphetamine injection, and at least 4
contralateral rotations/min in response to apomorphine
injection were selected for further unlabeled and MNPs-
labeled hVM cell transplantation studies, performed
under the same conditions as described above for intact
rat brains, but transplanting cells into the right 6-OHDA
lesioned striatum . The animals were immunosuppressed
with daily intraperitoneal cyclosporin A injection
(15 mg/kg; Novartis), starting 2 days before trans-
plantation and throughout the experiment.
For in vivo studies, we analyzed the animals at 48 h
and from 2 weeks to 5 months following transplantation.
Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (MRI) was performed in
the C.A.I. Nuclear Magnetic Resonance and Electron
Spin Centre at Complutense University of Madrid. We
used the Biospec BMT 47/40 (Bruker, Ettlingen, Germany),
which operates at 4.7 Tesla and is equipped with a gradient
shield system active of 12 cm. Rats were anesthetized with a
mixture of oxygen and isoflurane. Once anesthesized the
animals were placed in prone position on a plate of 7 cm in
length, head immobilized and connected to a radiofre-
quency probe to monitor their cardiac and respiratory fre-
quency, and temperature of the animal during image
acquisition. First global parameters were determined for
centering and optimal collection of images in T2 *. Then,
three images of spin echo were run in axial, sagittal, and
coronal orientation (TR / TE = 200/10 ms, matrix =
128x128). Transplanted cells labeled with MNPs were visu-
alized performing a gradient-echo sequence using the
Ramos-Gómez et al. Journal of Nanobiotechnology  (2015) 13:20 Page 5 of 15following parameters: TR = 250 ms, TE = 10 ms, rotation
angle = 30 °, thickness of section = 1 mm, number of slices =
8, mean number = 6, FOV= 3x3 cm 2, matrix = 256x192.
The reconstructed matrix size was 256 x 256. The acquisi-
tion time for these experiments was 4 minutes and
48 seconds. The images were subsequently analyzed with the
ImageJ program.
Immunohistochemistry
At the end of the experiments, the animals were anes-
thetized with an overdose of chloral hydrate and intra-
cardially perfused with freshly prepared, buffered 4%
paraformaldehyde (in 0.1 M phosphate buffer, pH 7.4).
Brains were removed, postfixed for 12 h in the same
fixative at 4°C, and dehydrated in 30% sucrose solution
at 4°C until sunk. Eleven 30 μm-thick coronal sections
were collected using a freezing microtome. Serial sections
were used for immunohistochemistry with polyclonal anti-
bodies against human Nestin (1:1000; Abcam), Ki67
(1:500, Neomarkers), Doublecortin (Dcx) (1:1000; Santa
Cruz Biotechnology) and monoclonal antibodies against
human GFAP (1:1000; Sternberger), human nuclei (hNu)
(1:100; Chemicon). Briefly, free-floating sections were in-
cubated overnight at 4°C with the primary antibodies di-
luted in PBS with 2% nonspecific serum. Sections were
rinsed three times in PBS for a total time of 1 h and then
incubated for 2 h with the secondary antibodies in PBS
(Cy5-conjugated Ab (anti-mouse or anti-rabbit (1:500)),
Cy3-conjugated Ab (antimouse or anti-rabbit (1:200), all
from Jackson Immunoresearch), and mounted onto poly-
lysine pre-treated glass slides (Menzel-Glaser). The slides
were dried and coverslipped with Mowiol.
For staining with DAB, first endogenous tissue perox-
idase activity was quenched using a 10% solution of
methanol and 3% H2O2 in PBS for 20 minutes. Subse-
quently, brain sections were washed with PBS and incu-
bated with blocking solution for 1 h. The sections were
then incubated with primary antibody anti OX42 (1:1000,
monoclonal, Chemicon) dissolved in a solution of PBS,
0.25% Triton X-100 and 1% horse serum overnight at 4°C.
After rinsing, sections were incubated for 2 h with biotinyl-
ated secondary antibody (anti-mouse BA2001, dissolved
1:200, Vector) at room temperature. Then sections were in-
cubated with a complex of avidin-biotin-peroxidase (ABC,
Vector) and developed with the chromogen 1,3 - diamino-
benzidine (DAB, dissolved in 0.05% PBS, 8% NiCl 2 and
0.03% H2O2 Sigma). Sections were washed in PBS and dis-
tilled H2O and mounted on slides treated with polylysine,
dried at room temperature over night, dehydrated by an
increasing gradient of ethanol (50% -90% -100%) and de-
lipidatted with xylene. Finally, slides were coverslipped with
DPX (BDH).
Analyses and photography of fluorescent or DAB
stained samples were carried out in an inverted ZeissAxiovert 135 (Oberkochen, Germany), LeicaDMIRB
microscope equipped with a digital camera Leica DC100
(Nussloch, Germany) or LSM510 laser confocal Microscope
coupled to a Axiovert200 (Zeiss) inverted microscope.
Results
Internalization of MNPs by VM hNSCs: cell viability, and
MNPs size and concentration effects
Different MNPs were compared to select the optimal
one to magnetically label VM hNSCs. We tested iron
MNPs (Fe3O4) with different core diameters: 50, 100
and 250 nm, all of them coated with dextran. The influ-
ence of different concentrations of MNPs on cell viabil-
ity was studied at incubation times of 72 h.We also
analyzed the effect of the transfection agents, PS and PL,
in the case of the lowest concentration of 50 nm MNPs
(50 μg/ml), to determine whether the transfection agents
could avoid the use of higher doses of NPMs.
The highest concentrations of nanoparticles tested
(100 and 300 μg/ml) produced a significant decrease in
cell viability, as evaluated by MTT assay (Figure 1A).
Moreover, 50 nm MNPs at 50 μg/ml in the presence of
PL produced a significant decrease in cell viability
(Figure 1B). In addition to the toxicity observed in the
MTT assay, the highest concentrations of particles
tested (100 and 300 μg/ml) induced a decrease in the
number of cells per field (phalloidin staining), and the
presence of numerous apoptotic nuclei stained with
Hoechst (Figure 1C).
Thus, labeling of the cells at doses of 50 μg/ml and
incubation times of 72 hours did not affect cell survival,
evaluated by MTT assay, and resulted in 80 to 90% label-
ing efficiency (see below). This is valid for all sizes of
nanoparticles tested (Figure 1A). These results led us to
conclude that labeling hNSCs with MNPs did not sig-
nificantly affect cell viability, using concentrations of
50 μg/ml for 72 h. Based on these results, we decided to
use 50 μg/ml of MNPs for subsequent studies.
Effects of the incubation time and transfection agents
used on the internalization of MNPs by VM hNSCs.
It has been previously reported that cationic transfection
agents might improve the efficiency of MNPs intra-
cellular uptake [19,26-29], especially in non-phagocytic
cells. Thus, the ability of cationic compounds such as PL
and PS might increase the capacity of VM hNSCs to
internalize MNPs.
MNPs uptake was assessed by quantifying the number
of cells that displayed fluorescent intracellular labeling
of MNPs, as described in the methods section (see also
Figure 1C). hVM cells were incubated for different times,
ranging from 3 to 72 h, with 50 μg/ml of 50, 100 and
250 nm MNPs, since we had previously demonstrated
that this dose did not affect cell viability in most
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Figure 1 Cell viability in the presence of MNPs. A. hVM cells were incubated in the presence of 250, 100 and 50 nm in diameter MNPs for
72 h at increasing concentrations, ranging from 50 to 300 μg/ml. Doses up to 50 μg/ml did not significantly affect cell viability, as evaluated by
MTT assay. B hVM cell viability (by MTT assay), after 72 h in the presence of 250, 100 and 50 nm MNPs at 50 μg/ml using poly-L-Lysine (PL) and
protamine sulfate (PS) as transfection agents. Only PL produced a significant decrease in cell viability. C hVM-MNPs-Cy3 treated cells were fixed
after 72 h and stained with Phalloidin A488. Nuclei were counterstained with Hoechst. Scale bar 20μm. Data represent mean +/- S.E. (n = 4).
(*p <0.05, ANOVA, post hoc Tukey’s test; * versus hVM cells treated with 0 μg/ml MNPs).
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positive correlation between the uptake of MNPs and
the incubation times for all types of MNPs tested. In the
case of 50 nm MNPs coated with PL, uptake was max-
imum at all incubation times studied, indicating that
both the size of the particle and the presence of the poli-
cationic agent PL significantly influence the time needed
to label nearly 100% of the cells. PS had no effect for the
50 nm particles. The largest MNPs tested, 250 nm, were
the ones uptaken most slowly by hVM cells, even whenPS or PL were added as transfection agents (Figure 2A).
To demonstrate an efficient labeling of hVM cells with
MNPs, a semi-quantitative assessment (Image J, NIH) of
100 nm MNPs fluorescence signal was performed in
hVM cells comparing this signal to a well established
SPIO uptake by a common cell line (COS cells) [30]
indicating that the uptake of MNPs by hVM cells was
similar to that observed in COS cells (Figure 2B).
MNPs with a diameter of 50 and 100 nm were the
most appropriate MNPs to label hVM cells at short
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Figure 2 Incorporation of MNPs by hVM cells and persistence of the MNPs load over time. A. The incorporation of 50 μg/ml MNPs-Cy3 of
50, 100 and 250 nm in diameter by hVM cells was evaluated as percentage of Cy-3 labeled cells at 3, 6, 24 and 72 h. The effect of poly-L-Lysine
(PL) and protamine sulfate (PS) was also evaluated in the uptake of 50 nm and 250 nm MNPs. Incubation times up to 72 h resulted in nearly
100% labeling efficiency even in the absence of PL or PS. B. hVM and COS cells were incubated with 100 nm MNP-Cy3 at 50 μg/ml for 3, 6, 24
and 72 hours. The sum of MNP-Cy3 area represents the total area occupied by nanoparticles-Cy3, measured by Image J (NIH) in units of pixels,
corrected by the number of cells present in each field. C. hVM cells were labeled with 50 and 100 nm MNPs (50 μg/ml) for 72 h and serially subcultured
to test the persistence of MNPs labeling after passages. The decreased numbers of MNP-labeled cells observed at progressive subculturing
passages indicated that both 50 and 100 nm MNPs are progressively diluted over time.
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than 90% of the cells were labeled with MNPs in all condi-
tions tested. The increase in the percentage of labeled cells
provided by transfection agents can also be achieved in-
creasing the incubation time with the MNPs. Thus, since
these chemical agents induce a decrease in cell viability,
especially PL in the case of 50 nm MNPs (Figure 1A), tox-
icity may be avoided by lengthening the incubation times
with the MNPs.
Persistance of the MNPs load over time
To determine whether the MNPs were retained by hVM
cells after passages, cells were incubated with 50 μg/ml
of MNPs for 3 days (p0) and then passaged. At each sub-
culturing passage, a fraction of the cells was plated separ-
ately and evaluated for the percentage of cells retaining
MNP labeling. Dextran staining confirmed a labeling effi-
ciency over 95% at passage 0 (Figure 2C). A progressive
drop in the number of dextran-labeled cells with passages
was observed, indicating that intracellular MNPs (both 50
and 100 nm sizes), were progressively diluted over time,
likely due to cell proliferation. The labeling rate was simi-
lar for both nanoparticles 50 and 100 nm after the 2nd and3rd passages. However, the 50 nm MNPS were retained by
the cells much better than the 100nM ones after passage 1
(Figure 2C).
Effects of MNPs on cell cycle
Analysis of cell replication was determined by fluores-
cence labeling of the nuclei of the cells in suspension
using propidium iodide, and then analyzing the fluores-
cence properties of each cell in the population by flow
cytometry [25]. This study was conducted to determine
whether the presence of MNPs was compatible with a
normal cell cycle progression in hVM cells. To this end,
the cells were exposed to MNPs for 24 and 48 h, and
the distribution of cells in the different cell cycle phases
was determined.
The percentage of cells in G0-G1, S and G2-M phases
was assessed in both control and labeled cells (incubated
with 50 μg/ml of 100 nm MNPs). Analysis of the DNA
content between samples showed an identical distribu-
tion of cells in the different cell cycle phases at both
time points (Figure 3). Therefore, MNP labeling of VM
hNSCs does not alter cell cycle dynamics. The sub G0-
G1 fraction (fragmented DNA) was also quantified to
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Figure 3 Effects of MNPs on cell cycle. hVM cells were either
untreated or treated with 50 μg/ml of 100 nm MNPs for 24 and
48 h. Cell cycle analyses were performed by flow cytometry after
staining with propidium iodide (PI). The intensity of the PI signal is
directly proportional to the DNA content in each phase (G0-G1
phase, S phase, G2-M phase). The percentage of cells in each cell
cycle phase showed similar cell cycles profiles for labeled and
unlabeled cells.
Ramos-Gómez et al. Journal of Nanobiotechnology  (2015) 13:20 Page 8 of 15assess cell death by flow cytometry. No cells were
detected in subG0 phase in both conditions indicat-
ing that the addition of MNPs did not induce cell
death, measured as DNA fragmentation (data not
shown), consistent with the results of the MTT assay
(Figure 1).0
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100 nm MNPs at 50 μg/ml for 72 h. B. The presence of neurons (β-III-Tubu
assessed in hVM cells differentiated for 7 days after labeling them with 50
β-III-Tubulin, TH and GFAP in 7-day differentiated hVM cells either unlabele
counterstained with ToPro3. No significant differences were observed in th
morphology in MNPs-labeled cells with respect to unlabeled cells. Scale baEffects of MNPs on cell stemness and differentiation
The expression of nestin, a typical marker of neural stem
cells, was analyzed in hVM cells labeled with MNPs of
different sizes (50 and 100 nm) at 50 μg/ml for 72 h.
The percentage of nestin-positive cells in MNPs-labeled
hVM cells and in control cells was quantified, and found
to be the same in all the studied cultures (Figure 4A).
Therefore, MNPs do not induce differentiation themselves.
To assess the differentiation potential of MNPs-
labeled hVM cells, after labeling the cultures were subse-
quently differentiated for 7 days and stained for β-III-
tubulin, tyrosine hydroxylase (TH) and glial fibrillary
acid protein (GFAP), and counterstained with Hoechst
(DNA stain). The percentage of total cells expressing
markers characteristic of differentiated VM hNSCs, like
β-III-tubulin, GFAP and TH, was compared among sam-
ples (Figure 4B, C). No significant differences between
control and MNPs-labeled cells were observed, demon-
strating that MNPs do not affect the ability of hVM cells
to differentiate into glial cells, neurons and, specifically,
dopaminergic neurons, obtaining similar results for TH-
and β-III-tubulin-positive cells (17% and 25% respect-
ively) to those previously described in [7]. Thus, these
results demonstrate that labeling VM hNSCs cells with
optimal doses of MNPs does not affect their stemness
and differentiation potential.Control MNPs 100nm
entage of nestin positive hVM cells after labeling cells with 50 and
lin+), dopaminergic neurons (TH+) and astrocytes (GFAP+) cells was
and 100 nm MNPs at 50 μg/ml for 72 h. C. Immunocytochemistry for
d (control) or labeled with 100 nm MNPs-Cy3 (in red). Nuclei were
e relative proportions of the different neural cell types or in their
r: 25 μm.
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To study the subcellular distribution of MNPs uptaken
by VM hNSCs, the cells were incubated with 50 and
100 nm MNPs at 50 μg/ml for 72 h, and differentiated
afterwards. After that time, proliferation medium was
changed to differentiation medium for 4 days. Staining
with an anti-dextran antibody or fluorophores directly
coupled to MNPs, allowed us to track the intracellular
location of the MNPs. To unambiguously determine
if the detected NMPs were adhered to the plasma
membrane of they were internalized/compartimentalized,
series of images were taken along the XZ and XY planes
under a confocal microscopy. The orthogonal projections
in Figure 5A-B demonstrate that 50 and 100 nm MNPs
did not remain superficially attached to cell membranes;
on the contrary they were endocytosed by hVM cells.
To determine the final intracellular localization of the
MNPs, different fluorescent antibodies, specific for early
endosomes (antiEEA1), Golgi apparatus (manoxidase) and
lysosomes (CD63) were used. Staining of the endosomes
demonstrated that the green signals, labeling endosomes,
and the MNPs, labeled in red, are located within the cyto-
sol but do not co-localize (Figure 5C). Golgi apparatus
(Figure 5D) and lysosomes (Figure 5E) both stained in
green, do not co-localize with MNPs-Cy3 either.
These results indicate that MNPs are internalized by
hVM cells labeling the cytosolic compartment, without
being sequestered by endosomes, lysosomes or other
subcellular organelles, as identified with the markers
used in the present assays. In conclusion, the intracellularA
C D
Figure 5 Intracellular location of MNPs on hVM cells. A-B. hVM cells w
for 72 h. After fixation, cells were stained with Phalloidin A488 (green). MN
Orthogonal projections are shown in A and B, confirming the colocalization
localization of MNPs-Cy3, hVM cells were incubated with 100 nm MNPs-Cy3 a
anti-mannosidase II specific for Golgi apparatus (D) and anti-CD63 specific for
bars: 10 μm in A-B and 15 μm in C-E.localization of MNPs in VM hNSCs makes them well
suited for MRI analyses.MRI analysis of MNP-labeled hVM cells after
transplantation
Having established an optimized procedure to label
hVM cells with MNPs (50 μg/ml of 100 nm MNPs
for 72 h) we proceeded to transplant them into right
striatum (Figure 6). MRI was performed at different
times after cell transplantation (48 h, 2, 4 and 8 weeks).
The same number of hVM cells without MNPs were
transplanted in the left striatum as an internal imaging
control. Strong MRI contrast was observed in the right
striatum. No MRI signal was detected when similar
numbers of unlabeled cells were injected in the contra-
lateral striatum (Figure 6). The MNPs-labeled hVM cells
can be detected from 48 h to 8 weeks after transplant-
ation (Figure 6). 48 h after transplantation, labeled hVM
cells are clearly visualized by MRI as a large hypointense
signal in the area of the transplant. Although the inten-
sity and size of the magnetic resonance signal decreases
slightly during the time periods studied, it is still clearly
visible even at 8 weeks after transplantation (Figure 6D).
The slight decrease in MRI signal over time might be
due to the migration of a small percentage of hVM cells
through the corpus callosum that reach this area follow-
ing the injection tract (arrow in Figure 6C). This observ-
able fact demonstrates that the technique is also valid
for tracking small migrating cell populations.B
E
ere incubated with 50 nm (A) and 100 nm MNPs-Cy3 (B) at 50 μg/ml
Ps in A were detected by staining with an anti-dextran antibody (red).
of MNPs and phalloidin. C-E. To determine the final intracellular
t 50 μg/ml for 72 h, antibodies anti-EEA1 specific for early endosomes (C),
lysosomes (E), were used. Nuclei were counterstained with ToPro3. Scale
A B
C D
48h 2weeks
8weeks4weeks
Left Right
Figure 6 MR imaging of hVM-MNP labeled cells in rat brain. Cell
suspensions (3x105 cells) were transplanted into the left (hVM cells)
and right (hVM-MNP-Cy3 labeled cells) intact striata. MRI was
performed 48 h (A), 2 weeks (B), 4 weeks (C) and 8 weeks (D) after
cell transplantation. MNPs can be easily detected by MRI as dark
hypointense signals in the area where the MNPs-labeled cells have
been injected. No MRI signal was detected when unlabeled hVM
cells were transplanted (left striatum). The arrow in C shows a small
percentage of hVM cells following the injection tract. Scale
bar: 2 mm.
B
C D
F
G H
A
E
Figure 7 MR imaging of hVM-MNP labeled cells one week and
two months after transplantation into hemiparkinsonian rat
brains. hVM-MNP-Cy3 labeled cells (3x105 cells) were detected by
MRI one week (arrow in A) and two months (arrow in E) after
transplantation into the right striatum of 6-OHDA-lesioned rat
brains. Analyses by fluorescence microscopy showed that MNPs-Cy3
were clearly visible in red in coronal sections from striatum one week
(B) and 2 months (F) after cell transplantation. Transplants were stained
for hNu (blue in C, D, G) to detect hVM cells; Ki67 (purple in C, arrows
point to Ki67 stained cells, showing a purple color, slightly different
from MNPs-Cy3 marked in red); human Nestin (red in D and G, inserts
in D and G) and human GFAP (blue in H and insert in H). Scale bars:
5 mm in A and E, 50 μm in B-D, F-H; 20 μm in inserts in D, G-H.
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and the advantage of visualizing transplanted cells
within their anatomical surroundings, which is crucial
to check the correct position of the cells after trans-
plantation and the visualization of the cell migration
processes.
Histological analysis of MNPs-hVM cells after
transplantation
The localization of MNPs inside the cells after trans-
plantation was performed using confocal fluorescence
microscopy. One week after MNP-hVM cells transplant-
ation in hemiparkinsonian rats, MNPs were identified by
MRI scans previous to sacrifice (Figure 7A). Red fluores-
cent MNPs were evenly distributed throughout the
transplant region (Figure 7B). Immunocytofluorescence
to detect hVM cells was carried out using an antibody
anti-human nucleus (Figure 7C). One week after trans-
plantation, hVM cells present an immature phenotype,
as evidenced by the fact that most of these cells are still
nestin-positive (Figure 7D). Furthermore, a small per-
centage of hVM cells are Ki67-positive (Figure 7C), indi-
cating that one week after transplantation some hVM
cells are still dividing.
As it has been previously described, two months after
transplantation the location of MRI signal is the same to
that obtained few hours after transplantation, although
there is a slight decrease in signal size and intensity
(Figure 6A and D). Analyses by fluorescence micros-
copy, showed that 2 months after transplantation, theMNPs were aggregated around the limits of the trans-
plant zone, with less intense signal in the graft core
(Figure 7F). At this time some hVM cells are still nestin
positive (Figure 7G), but some GFAP positive cells
are present in the area of the transplant (Figure 7H),
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in transplanted hVM cells.
Long term MRI analysis
5 months after cell transplantation, a clear hypointense
signal at the site of the transplantion is still visible
(arrow in Figure 8 A). This signal is quite similar in in-
tensity and size, to that obtained at 2 months after trans-
plantation (Figures 6D and 7E). MNPs maintained their
fluorescence five months after transplantation and can
be detected in brain sections by fluorescence microscopy
(Figure 8B). However, MNPs were found mainly in the
boundaries of the transplantation area forming large ag-
gregates outside the cells (arrows in Figure 8B). hVM
cells identified by hNu immunoreactivity were predom-
inantly positive for nestin (Figure 8C and insert) and forA B
C
D
E
F
Figure 8 MR imaging of hVM-MNP labeled cells 5 months after
transplantation into hemiparkinsonian rat brains. hVM-MNP-Cy3
labeled cells (3x105 cells) were detected by MRI 5 months (arrow in
A) after transplantation into the right striatum of 6OHDA-lesioned
rat brains. Analyses by fluorescence microscopy showed that
MNPs-Cy3 were clearly visible in red in coronal sections from striatum
5 months after cell transplantation (B, D). Transplants were stained for
hNu (blue in C) to detect hVM cells; Nestin (red in C and insert in C);
human GFAP (blue in D and E, orthogonal projections are shown in E,
confirming the colocalization of GFAP and MNPs-Cy3) and OX42
(stained with DAB) combined with red fluorescence to visualize
MNPs-Cy3 (F). Scale bars: 2 mm in A, 100 μm in B-D; 10 μm in insert in
C, E-F.GFAP (Figure 8D). As expected, the presence of MNPs
inside hVM cells was detected, in both nestin (data not
shown) and GFAP (Figure 8E). Neurons were not de-
tected in the present experiment. It is important to high-
light at this point that human neurons mature very
slowly, even when fresh VM tissue is used (over half a
year) [31-33]. In fact in other studies using hVM cells we
have only observed immature neuronal morphologies
[5]. Currently, we are conducting a one-year long experi-
ment to allow the transplant enough time for full
maturation.
In the striatum, and especially surrounding the area of
the transplant, we can observe the presence of cells of
the microglial lineage stained by OX42 (Figure 8F). This
microglial reactivity is especially strong in the area sur-
rounding the transplanted MNPs-hVM cells. This OX42
labeling is not observed in brain sections from animals
in which unlabeled cells were transplanted (data not
shown).The strongest OX42 signal is detected especially
in the boundaries of the MNP-hVM cells transplanted
area, coinciding with the area where the nanoparticles
are more abundantly found. OX42 positive microglial
cells co-localized with the signal from MNPs, suggesting
that MNPs are removed from the brain parenchyma by
microglial cells.
Discussion
The efficient application of stem cells for the treatment
of neurodegenerative diseases requires safe cell tracking
to follow stem cell fate over time in the host after trans-
plantation. The present study illustrates the use of com-
mercial nanoparticles to label human neural stem cells
without using any transfection agents, for long term
tracking by MRI after their transplantation.
In general, most nonphagocytic cells do not take up
MNPs efficiently or require cells to be exposed to high
amounts of iron in culture [21,22,34-36]. Most magnetic
nanoparticles require transfection agents for adequate
internalization by stem cells, although it has been re-
ported that Feridex complexed with PL blocked the dif-
ferentiation of human MSCs into chondrocytes [37].
Only very small superparamagnetic iron oxide particles
with a core diameter of 5 nm have been used to label
human mesencephalic neural precursor cells [14]. Our
data show that nearly 100% of hVM cells were labeled
with MNPs of different sizes (50 and 100 nm) in the
absence of any transfection agents. These results are
similar to those obtained in human NSCs using PS [38]
or PL [23,38] as transfecting agents. The present method
showed very clean labeling with minimum extracellular
iron nanoparticles. These results indicate that with rela-
tively low concentrations of iron (ie, 50 μg of iron per
milliliter) in culture media, an almost complete cellular
labeling with MNPs can be achieved.
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cell cycle of MNPs-labeled hVM cells was unaffected,
coinciding with findings from other studies, in which
MNPs were used to label embryonic stem cells [39],
hematopoietic progenitor cells [19] and bone marrow
stromal cells [40]. Thus, this procedure that avoids the
use of transfecting agents can be considered safe for cell
labeling.
We demonstrate the presence of MNPs in the hVM
cytosol indicating that MNPs are incorporated by hVM
cells via endocytosis. Uptake of 50 nm, 100 nm and
250 nm MNPs at 50 μg/ml occurred in almost 100% of
hVM cells, after an incubation period of 72 h without af-
fecting hVM cells survival rate, as evaluated by MTT
assay. When using higher concentrations of MNPs
(100-300 μg/ml) a significant decrease in cell viability
was observed. These results are in agreement with
other observations on MNPs-labeling of human NPCs
that had no adverse effects on cell survival [23]. However,
functional tests in rats transplanted with MNPs-labeled
hVM cells must be performed to exclude adverse effect of
the MNP labeling on functional outcome of the trans-
planted rats. Also, before thinking in a future clinical
translation, oxidative damage as the one described in mes-
enchymal stem cells by MNPs [41] should be evaluated,
even in the absence of effects of cell proliferation, cell
viability and cell death as demonstrated in the present
study with hNSCs.
Loss of MNPs over time
Intracellular MNPs were progressively diluted and al-
most completely undetectable by immunocytochemistry
after 3 subculturing passages. Predicted dilution of
MNPs inside hVM cells was most likely due to cell div-
ision. Loss of MNPs due to cell proliferation or differen-
tiation has previously been reported for different cell
types labeled with different types of MNPs [42-45]. This
fact may hinder the reliable long term cell tracking by
MRI after cell transplantation [46], in case the cells
would have a large replication potential in vivo.
MNPs-labeled hVM cells maintain their stemness and
differentiation potential
The feasibility of cell-based therapies depends upon the
ability of transplanted cells to maintain their proposed
therapeutic functions in vivo. Previous studies have re-
vealed that hVM cells differentiate into a high percent-
age of dopaminergic neurons [8,9]; this characteristic
makes them particularly attractive for cell replacement
therapy in Parkinson’s disease. It has been also demon-
strated that most stem cells labeled with MNPs retain
their regenerative and therapeutic potential in vivo
[38,47]. In order to assess that the optimized labeling
protocols did not affect the stemness or differentiationpotential of hVM cells, we analyzed the presence of nes-
tin, a typical marker of neural stem cells, in cells treated
with MNPs compared with control unlabeled cells. As
described in the Results section, the labeling of hVM
cells with MNPs did not affect lineage commitment dur-
ing the differentiation period of hVM cells. We have an-
alyzed the percentage of TH± neurons generated after
7 days of differentiation. Labeling hVM cells with MNPs
did not affect the percentage of TH+ cells obtained dur-
ing the differentiation process. We did not observe any
significant changes in the percentage of nestin, GFAP or
β-III-tubulin hVM cells compared to MNPs-hVM cells,
after 7 days of differentiation. These results confirm pre-
vious data reported in human [14,23,48] and mouse [12]
neural precursor cells labeled with ferumoxides. How-
ever, it has been observed that MNPs could cause mor-
phological changes and alterations in the differentiation
pattern of human adult mesenchymal stem cells [37,49]
but not in mouse mesenchymal stem cells [50]. In
the present study with hNSCs, we did not observe any
morphological alteration of the labeled and differentiated
cells in vitro. On the contrary to these findings, others
have demonstrated an increase in GFAP expression and
changes in cell morphology when treating hNPCs with
Au- and Ag-nanoparticles [51].
Using confocal microscopy, the nanoparticles did not
co-localize with any of the markers of the subcellular
organelles analyzed (endosomes, lysosomes, endoplasmic
reticulum or Golgi apparatus). This suggests that these
nanoparticles can be freely distributed in the cytoplasm
and eventually enter the normal iron metabolic pathways
[26]. However, further electron microscopy analysis must
be carried out to unequivocally determine the exact sub-
cellular localization of the nanoparticles.
MRI and hVM cells
Previous studies have shown that magnetically labeled
cells maintained their contrast for 6 weeks [44], 1 month
[47] and even 3 months after transplantation [14], sug-
gesting that labeling cells with MNPs can be a suitable
method for cell tracking by MRI over time. However,
long term analysis after cell transplantation might be de-
ceiving, especially if transplanted cells continue dividing
in the host brain [52]. As shown here, MNPs-labeled cells
show a gradual reduction in intracellular iron particles
after 2 or 3 passages in cell cultures. Therefore, dilution
but also the loss of MNPs from transplanted cells to the
host brain parenchyma might occur during cell division.
MNPs released to the host parenchyma during cell
division, exocytosis processes or even after cell death, can
contribute to the MR signal.
In short term MRI analyses (1 week and 2 month after
cell transplantation) we observed an excellent agreement
between the areas of MR contrast enhancement and
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conclude that this technique could also be valid to assess
the precise position of the grafted cells shortly after
transplantation.
However, long term MRI analyses are needed to per-
form because transplanted cells are expected to slowly
mature into the correct phenotypes and participate to
some extent in tissue reconstruction (over half a year).
Our results showed that there were still some nestin
positive hVM cells at 5 months post-transplantation. Al-
though at that time we found numerous GFAP positive
cells, grafted cells mainly express progenitor markers at
short times after transplantation [45]. The ability of hu-
man embryonic stem cell neurons to provide extensive
reinnervation of the host striatum and begin to restore
DAergic neurotransmission have been described at least
6 months post-transplantation [53]. This is in line with
previous clinical observations using human fetal VM
grafted to patients, where progressive recovery of DA
neurotransmission starts at 6 months, reflecting the
gradual maturation of the transplanted cells [54]. Similar
results have been recently described when using human
pluripotent stem cells (hPSCs). Functional maturation of
hPSC-derived neurons requires an extended timeline of
up to seven months, mimicking endogenous human
neural development [55].
Although some studies found no co-localization of
mouse macrophages and iron-containing areas of brain
tissue [56] this event has been described previously in a
spinal cord injury model transplanted with Endorem-
labeled mesenchymal stem cells [57]. In our case, long
term MRI analyses followed by histological analyses (up to
5 months after cell transplantation) showed that MNPs
can be found in the brain parenchyma co-localizing with
areas rich in markers of reactive microglia, like OX42.
This fact is a cause of concern because of the possible false
positive interpretation of the MRI signal, which may be
produced by macrophages that have engulfed some non-
viable labeled NSCs or freely-dispersed iron nanoparticles
in the brain tissue [58].
Conclusion
NSCs are one of the most attractive cells sources for
stem cell therapies of neurodegenerative diseases. For
therapeutic application, transplanted cells need to be
tracked both spatially and temporally in the living brain,
in order to assess their migration and survival in the
host tissue. Therefore, for the application of these tech-
niques in vivo, additional live imaging tools such as MRI
are necessary. The procedures described here are suit-
able for studying the in vivo localization and migration
of grafted human neural stem cells in longitudinal stud-
ies. We have shown that labeling of hVM cells with
MNPs does not affect their overall biology, survival rateand in vitro differentiation. These findings support the
use of commercial MNPs to track cells for short- and
mid-term periods after transplantation for studies of
brain cell replacement therapy. Nevertheless, long-term
MR images should be interpreted with caution due to
the possibility that some MNPs may be expelled from
the transplanted cells and internalized by host microglial
cells.
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